Healios K.K. (OTCMKTS:HLOSF) Sees Significant Drop in Short Interest

Healios K.K. (OTCMKTS:HLOSF) was the recipient of a significant drop in short interest in April. As of April 30th, there was short interest totaling 263,933 shares, a drop of 34.6% from the April 15th total of 403,733 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Healios K.K. Price Performance

HLOSF remained flat at $2.20 on Tuesday. Healios K.K. has a 52 week low of $1.90 and a 52 week high of $4.45. The stock has a 50 day moving average of $2.40 and a two-hundred day moving average of $2.45.

Healios K.K. Company Profile

Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.

Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.